In routine UK clinical practice, oral semaglutide reduced HbA1c by 1.1 percentage points and body weight by 4.4 kg over 34-44 weeks, with high patient satisfaction.
-1.1% HbA1cOral semaglutide reduced HbA1c by 1.1 percentage points in routine UK clinical practice, confirming clinical trial benefits translate to the real world
What the researchers found
Oral semaglutide reduced HbA1c by 1.1 percentage points (95% CI -1.27 to -0.96, P<0.001) and body weight by 4.4 kg in real-world UK clinical practice. 36.4% achieved combined HbA1c reduction plus ≥3% weight loss; 27.1% achieved HbA1c reduction plus ≥5% weight loss. No severe hypoglycemia or new safety signals.
Why it matters
Clinical trials show what a drug can do under ideal conditions. Real-world studies show what it actually does in everyday practice. This study confirms that oral semaglutide delivers meaningful blood sugar and weight benefits outside of tightly controlled trial settings, which is more relevant to typical patients.
The numbers in context
333 participants enrolled. Follow-up: 34-44 weeks. Treated as part of routine clinical care.
How the study worked
Multi-centre, prospective, non-interventional single-arm study (PIONEER REAL UK). 333 adults with T2D enrolled across UK sites and followed for 34-44 weeks. All treated with oral semaglutide as part of routine clinical practice. No prior injectable glucose-lowering medication. Primary endpoint: HbA1c change. Secondary: body weight change, proportion meeting combined targets, treatment satisfaction (DTSQ).
Who was studied
Adults with type 2 diabetes in the UK treated with oral semaglutide
What this study cannot tell us
Single-arm study with no control group — observed changes could partly reflect regression to the mean or concurrent lifestyle changes. 227 of 333 participants remained on treatment at end of study (32% dropout). Selection bias possible as physicians chose patients they deemed suitable. UK-specific results may not generalize to all healthcare systems.
How to read the evidence
Rated moderate: prospective, multi-centre real-world study with good sample size, but limited by single-arm design (no control group) and a notable dropout rate.
When this study was published
Published in 2024. Part of the global PIONEER REAL study program evaluating oral semaglutide across multiple countries.
The bigger picture
Oral semaglutide represents a significant advance in GLP-1 peptide therapy by eliminating the injection barrier. These real-world results from the UK healthcare system suggest the clinical trial benefits translate to everyday practice, supporting broader adoption of this oral peptide formulation.
Questions still open
- How does real-world oral semaglutide performance compare to injectable GLP-1 agonists in head-to-head studies?
- What drove the 32% discontinuation rate — side effects, cost, or other factors?
- Would longer follow-up show sustained or increased benefits?
Common questions
Does oral semaglutide work as well as the injection?
What were the side effects of oral semaglutide in real-world use?
Read the original research
PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.
Advances in therapy, 41(11), 4266-4281
Citation
Saravanan, Ponnusamy; Bell, Heather; Braae, Uffe Christian; Collins, Edward; Deinega, Alisa; Dhatariya, Ketan; Machell, Alena; Trent, Antonia; Strzelecka, Anna. (2024). PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.. Advances in therapy, 41(11), 4266-4281. https://doi.org/10.1007/s12325-024-02973-z